Test Id : PLAIF
Phospholipase A2 Receptor (PLA2R), Renal Biopsy
Useful For
Suggests clinical disorders or settings where the test may be helpful
Method Name
A short description of the method used to perform the test
Immunofluorescence
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
RBPLA2RIF
RBNEGPLA2RIF
Specimen Type
Describes the specimen type validated for testing
Special
Ordering Guidance
This test will report as negative or positive for autoantibodies to phospholipase A2 receptor.
If additional interpretation/analysis is needed, request PATHC / Pathology Consultation along with this test and send: 1) the corresponding renal pathology light microscopy and immunofluorescence (IF) slides (or IF images on a CD); 2) electron microscopy images (prints or CD); and 3) the pathology report.
Shipping Instructions
1. Advise shipping frozen specimens (unstained slides or tissue block) in Styrofoam transportation coolers filled with dry ice to ensure specimens are received at required specimen stability temperature.
2. Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.
Necessary Information
A pathology/diagnostic report is required.
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Submit only 1 of the following specimens:
Preferred:
Specimen Type: Unstained slides (unfixed)
Source: Kidney tissue
Slides: 2 Slides
Collection Instructions: 2 frozen tissue unstained positively charged glass slides (25- x 75- x 1-mm) per test ordered; sections 4-microns thick, centered on the slide, and submitted on dry ice.
Acceptable:
Specimen Type: Unfixed tissue block (O.C.T)
Source: Kidney tissue
Specimen Volume: Entire specimen
Collection Instructions:
1. Embed in O.C.T. compound.
2. Freeze specimen and ship on dry ice.
Acceptable:
Specimen Type: Wet tissue
Source: Kidney tissue
Supplies: Renal Biopsy Kit (T231)
Container/Tube: Renal Biopsy Kit, Zeus/Michel's
Specimen Volume: Entire specimen
Collection Instructions: Collect specimens according to the instructions in Renal Biopsy Preparation Instructions.
Additional Information: If standard immunoglobulin and complement immunofluorescence have already been performed, submit the residual frozen tissue (must contain glomeruli) on dry ice.
Special Instructions
Library of PDFs including pertinent information and forms related to the test
Forms
1. Renal Biopsy Patient Information
2. If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
See Specimen Required
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Special | Frozen | ||
Useful For
Suggests clinical disorders or settings where the test may be helpful
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Membranous nephropathy is the most common cause of nephrotic syndrome in White adults. Eighty-five percent of membranous nephropathy cases are primary or idiopathic, and the other 15% are secondary. Phospholipase A2 receptor (PLA2R) is an antigen located on podocytes. The majority of cases of primary membranous nephropathy have circulating autoantibodies against PLA2R.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
An interpretive report will be provided.
Interpretation
Provides information to assist in interpretation of the test results
This test, when not accompanied by a pathology consultation request, will be reported as either positive or negative.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
No significant cautionary statements.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Larsen CP, Messias NC, Silva FG, Messias E, Walker PD. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2013;26(5):709-715
2. Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839-1844
3. Cossey LN, Walker PD, Larsen CP. Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy. Pediatr Nephrol. 2013;28(12):2307-2311
4. Larsen CP, Walker PD. Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy. Transplantation. 2013;95(10):1259-1262
5. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277-2287
Method Description
Describes how the test is performed and provides a method-specific reference
Indirect immunofluorescence staining on sections of frozen tissue.(Unpublished Mayo method)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
88346-primary IF
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| PLAIF | PLA2R Immunofluorescence | In Process |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 71225 | Interpretation | 59465-5 |
| 71226 | Participated in the Interpretation | No LOINC Needed |
| 71230 | Material Received | 81178-6 |
| 71229 | Gross Description | 22634-0 |
| 71227 | Report electronically signed by | 19139-5 |
| 71228 | Addendum | 35265-8 |
| 71617 | Disclaimer | 62364-5 |
| 71847 | Case Number | 80398-1 |